Claudia Lebedinsky

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text

Medicine, Oncology, Pharmacology +15

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye et al. · Journal of Clinical Oncology · 2010 · 404 citations

Medicine, Gynecology, Oncology +16

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer

Andrés Poveda, Stanley B. Kaye, Robert McCormack et al. · Gynecologic Oncology · 2011 · 178 citations

Medicine, Cell Biology, Oncology +17

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Andrés Poveda, Ignace Vergote, Sergei Tjulandin et al. · Annals of Oncology · 2010 · 168 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

Animesh Pardanani, Ayalew Tefferi, Catriona Jamieson et al. · Blood Cancer Journal · 2015 · 97 citations · Full text

Medicine, Hematology, Pharmacology +10